220 related articles for article (PubMed ID: 37084736)
1. Genomic mapping of metastatic organotropism in lung adenocarcinoma.
Lengel HB; Mastrogiacomo B; Connolly JG; Tan KS; Liu Y; Fick CN; Dunne EG; He D; Lankadasari MB; Satravada BA; Sun Y; Kundra R; Fong C; Smith S; Riely GJ; Rudin CM; Gomez DR; Solit DB; Berger MF; Li BT; Mayo MW; Matei I; Lyden DC; Adusumilli PS; Schultz N; Sanchez-Vega F; Jones DR
Cancer Cell; 2023 May; 41(5):970-985.e3. PubMed ID: 37084736
[TBL] [Abstract][Full Text] [Related]
2. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma.
Shih DJH; Nayyar N; Bihun I; Dagogo-Jack I; Gill CM; Aquilanti E; Bertalan M; Kaplan A; D'Andrea MR; Chukwueke U; Ippen FM; Alvarez-Breckenridge C; Camarda ND; Lastrapes M; McCabe D; Kuter B; Kaufman B; Strickland MR; Martinez-Gutierrez JC; Nagabhushan D; De Sauvage M; White MD; Castro BA; Hoang K; Kaneb A; Batchelor ED; Paek SH; Park SH; Martinez-Lage M; Berghoff AS; Merrill P; Gerstner ER; Batchelor TT; Frosch MP; Frazier RP; Borger DR; Iafrate AJ; Johnson BE; Santagata S; Preusser M; Cahill DP; Carter SL; Brastianos PK
Nat Genet; 2020 Apr; 52(4):371-377. PubMed ID: 32203465
[TBL] [Abstract][Full Text] [Related]
3. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis.
Talvitie EM; Liljeroos L; Vilhonen H; Orte K; Leivo I; Kallajoki M; Taimen P
Neoplasia; 2022 Oct; 32():100832. PubMed ID: 35964518
[TBL] [Abstract][Full Text] [Related]
5. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing.
Li D; Huang Y; Cai L; Wu M; Bao H; Xu Y; Wei Y; Wu S; Wu X; Shao Y; Zhao W; Lv G; Huang S; Zhang T; Shi Y
Neoplasia; 2021 Dec; 23(12):1204-1212. PubMed ID: 34735995
[TBL] [Abstract][Full Text] [Related]
7. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
Caso R; Sanchez-Vega F; Tan KS; Mastrogiacomo B; Zhou J; Jones GD; Nguyen B; Schultz N; Connolly JG; Brandt WS; Bott MJ; Rocco G; Molena D; Isbell JM; Liu Y; Mayo MW; Adusumilli PS; Travis WD; Jones DR
J Thorac Oncol; 2020 Dec; 15(12):1844-1856. PubMed ID: 32791233
[TBL] [Abstract][Full Text] [Related]
8. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
[TBL] [Abstract][Full Text] [Related]
9. A genetic portrait of metastatic seeds in lung adenocarcinoma.
Wu Q; Hu G
Cancer Cell; 2023 May; 41(5):828-830. PubMed ID: 37160102
[TBL] [Abstract][Full Text] [Related]
10. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
[TBL] [Abstract][Full Text] [Related]
11.
Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
[No Abstract] [Full Text] [Related]
12. Perspectives and Issues in the Assessment of
Armon S; Hofman P; Ilié M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
[TBL] [Abstract][Full Text] [Related]
13. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.
Karasaki T; Moore DA; Veeriah S; Naceur-Lombardelli C; Toncheva A; Magno N; Ward S; Bakir MA; Watkins TBK; Grigoriadis K; Huebner A; Hill MS; Frankell AM; Abbosh C; Puttick C; Zhai H; Gimeno-Valiente F; Saghafinia S; Kanu N; Dietzen M; Pich O; Lim EL; Martínez-Ruiz C; Black JRM; Biswas D; Campbell BB; Lee C; Colliver E; Enfield KSS; Hessey S; Hiley CT; Zaccaria S; Litchfield K; Birkbak NJ; Cadieux EL; Demeulemeester J; Van Loo P; Adusumilli PS; Tan KS; Cheema W; Sanchez-Vega F; Jones DR; Rekhtman N; Travis WD; Hackshaw A; Marafioti T; Salgado R; Le Quesne J; Nicholson AG; ; McGranahan N; Swanton C; Jamal-Hanjani M
Nat Med; 2023 Apr; 29(4):833-845. PubMed ID: 37045996
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
16. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
17. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
18. Mutational characteristics of bone metastasis of lung cancer.
Huang X; Shi X; Huang D; Li B; Lin N; Pan W; Yan X; Li H; Hao Q; Ye Z
Ann Palliat Med; 2021 Aug; 10(8):8818-8826. PubMed ID: 34488370
[TBL] [Abstract][Full Text] [Related]
19. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
20. Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.
Planck M; Edlund K; Botling J; Micke P; Isaksson S; Staaf J
PLoS One; 2013; 8(10):e78614. PubMed ID: 24205279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
